Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomnia

James K. Walsh, Milton Erman, C. W. Erwin, Andrew Jamieson, Mark Mahowald, Quentin Regestein, Martin Scharf, P. Tigel, Gerald Vogel, J. Catesby Ware

Research output: Contribution to journalArticlepeer-review

216 Scopus citations

Abstract

Trazodone is an antidepressant which is used at low doses as a hypnotic. The hypnotic efficacy of trazodone in non-depressed insomniacs is unknown, especially in comparison to hypnotic medications such as zolpidem. Following a placebo screening week, DSM-IIIR defined primary insomniacs were randomized into a parallel-group, double-blind, 14-day comparison of trazodone 50 mg, zolpidem 10 mg and placebo. Patients completed daily morning questionnaires and weekly office visits. Self-reported sleep latencies were compared by the Cox proportional hazards regression technique; self-reported sleep duration by ANOVA. During treatment Week 1, both drugs produced significantly shorter self-reported sleep latencies and longer self-reported sleep durations than placebo. Self-reported sleep latency was significantly shorter with zolpidem than with trazodone. During Week 2, only the zolpidem group maintained a significantly shorter sleep latency than the placebo group, and self-reported sleep duration did not vary significantly among groups. The incidence of adverse events was low in all groups. Both trazodone and zolpidem improved self-reported sleep latency and duration of non-depressed, primary insomniacs; zolpidem was somewhat more efficacious at the doses studied.

Original languageEnglish (US)
Pages (from-to)191-198
Number of pages8
JournalHuman Psychopharmacology
Volume13
Issue number3
DOIs
StatePublished - Apr 1 1998

Keywords

  • Hypnotic efficacy
  • Insomnia
  • Trazodone
  • Zolpidem

Fingerprint

Dive into the research topics of 'Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomnia'. Together they form a unique fingerprint.

Cite this